Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olpasiran in ASCVD Patients With Elevated Lipoprotein(a)
jRCT2031220596Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Dec 2022
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease and lipoprotein(a) hyperlipoproteinemia (Lp(a)) comparing Olpasiran with Placebo (2 arms). Primary endpoint: Time to CHD death, myocardial infarction, or urgent coronary revascularization. Started Dec 2022; status: active, not recruiting.
02
Drugs
olpasiran
03
Conditions
atherosclerotic diseaselipoprotein(a) hyperlipoproteinemia (Lp(a))
Beyond the preview
Go deeper on jRCT2031220596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220596.